Contact | Print version | PDF version | Send article | RSS feed

Bionas cell profiling device selected by Solvay Pharmaceuticals for Target Validation

10 Nov 2006 - Bionas GmbH and Solvay Pharmaceuticals Research Laboratories announce that the Bionas(R) 2500 analyzing system has been recognized to be a valuable tool for target validation studies.
 
"It is known that angiotensin 1-8 (angiotensin II) acts via two receptors. The AT1 receptor mediates vasoconstriction upon stimulation, whereas the AT2 receptor is implicated in hypotensive effects. However, the mechanism through which angiotensin 1-7 induces its powerful hypotensive effect were unclear," explains Dr. Eric Ronken, Principal Scientist at Solvay.
 
On-line monitoring of endothelial cell physiology and its changes upon challenges by angiotensin 1-7 helped in delineating the mechanism of action by this peptide. "The Bionas system allows us to extend and optimize target validation studies by bringing the targets back into their physiological context", says Dr. Eric Ronken.